KERX - Keryx Biopharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue60,64131,98313,680
Cost of Revenue25,03140,6896,644
Gross Profit35,610-8,7067,036
Operating Expenses
Research Development37,67929,50436,694
Selling General and Administrative99,62284,55381,410
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-101,691-122,763-111,068
Income from Continuing Operations
Total Other Income/Expenses Net-61,984-38,252-11,987
Earnings Before Interest and Taxes-163,675-161,015-123,055
Interest Expense---
Income Before Tax-163,675-161,015-123,055
Income Tax Expense-2358090
Minority Interest---
Net Income From Continuing Ops-163,440-161,095-123,145
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-163,440-161,095-123,145
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-163,440-161,095-123,145